Curadev's Differentiated Next Generation STING Agonist CRD3874-SI

Feb 15, 2024

Boston [US]/ Noida (Uttar Pradesh) [India], February 15: Curadev is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological...

Curadev Pharma announces the formation of its Clinical Advisory Group

Jan 04, 2023

Noida (Uttar Pradesh) [India], January 4 (ANI/PRNewswire): Curadev Pharma has created a Clinical Advisory Group (CAG) comprising eminent oncologists to provide guidance in the...

Curadev Pharma receives FDA 'Study May Proceed' Letter for its Investigational New Drug Application of CRD3874

Dec 06, 2022

Boston (Massachusetts) [US]/ Noida (Uttar Pradesh) [India], December 6 (ANI/PRNewswire): Curadev Pharma, a small molecule drug discovery and development company focused on the generation...

Curadev Announces First Treatment Cycle Completion for the First Patient Dosed in a Phase 1a/b Clinical Trial of Allosteric STING Agonist CRD3874-SI

Feb 29, 2024

Boston [US]/Noida (Uttar Pradesh) [India], February 29: Curadev, a drug discovery and development company, announced today a significant milestone in its development of drugs...